MCL1 and prostate cancer: of prostate cancer metastases showed that prostate cancer bone metastases had increased expression of MCL-1 (myeloid leukemia 1) and BCL-2 (B-cell lymphoma 2), key contributors in cell survival, compared to other sites of metastases (126–128).